Printer Friendly

BELMAC MARKETS SECOND PRODUCT IN FRANCE; COMPANY ACQUIRES AMODEX(TM) FROM FISONS PLC

 BELMAC MARKETS SECOND PRODUCT IN FRANCE;
 COMPANY ACQUIRES AMODEX(TM) FROM FISONS PLC
 TAMPA, Fla., Dec. 9 /PRNewswire/ -- Belmac Corporation (AMEX: BLM) announced today that it has begun the French distribution and marketing of Amodex(TM), an amoxicillin-based antibiotic. The drug was acquired from Laboratoires Gerbiol S.A., a subsidiary of Fisons PLC of England.
 Amodex(TM) will be distributed by Belmac's French sales force established to market the company's new macrolide antibiotic, Biolid(TM). "The strategy behind the acquisition of Amodex(TM) is quite simple and key to our goal of profitability for our French pharmaceutical business," explained Marc Ayers, chief financial officer of Belmac. "As we have a first-rate sales force already established, we are in an excellent position to acquire and market compatible ethical pharmaceutical products in the French market."
 Biolid(TM), developed by Belmac, is an augmented erythromycin derivative prescribed principally for infections of the upper and lower respiratory tracts. Amodex(TM), on the other hand, is a broad spectrum antibiotic that addresses a variety of bacterial infections. "The two antibiotics together allow us to provide the French medical community with a comprehensive approach for fighting bacterial infections," said Jean-Francois Rossignol, Ph.D., CEO of Belmac.
 Belmac acquired Amodex(TM) for $6.5 million ($36 million French Francs) of combined upfront cash payments and licensing fees. Currently, Amodex(TM) sales are approximately $5 million annually providing a profit margin of 65 percent without significant marketing support. "We intend to promote the product aggressively," explained Dr. Rossignol. "The team we have assembled to market Biolid(TM), led by general manager Jean-Pierre Hermet, has the experience and knowledge to market multiple products," commented Rossignol.
 Belmac Corporation, an international pharmaceutical company, is developing and marketing a broad range of antimicrobials such as Amodex(TM) (amoxicillin), Biolid(TM) (augmented erythromycin) and BM 40,501 (azaquinone), the latter being in late stages of pre-clinical development in the United States and Europe. Azaquinone is being developed as a treatment for drug resistant tuberculosis and other mycobacterial diseases including the prevention and treatment of mycobacterium avium complex (MAC) in HIV-positive individuals and AIDS patients. In addition, phenantramine, an anti-malarial drug, is expected to address the current worldwide crisis in the spread of resistant malaria. Alphanon(R), a transdermal drug, is intended for use in the treatment of the hemorrhoidal condition and potentially other venous disorders.
 -0- 12/9/91
 /CONTACT: Russell Ketchum, vice president of investor relations of Belmac Corporation, 813-286-4401 or 800-877-6533/
 (BLM) CO: Belmac Corporation; Fisons PLC ST: Florida IN: MTC SU: TNM


AW-SS -- FL002 -- 0431 12/09/91 09:57 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 9, 1991
Words:431
Previous Article:EXEL ANNOUNCES AGGREGATE EXCESS OF LOSS REINSURANCE ARRANGEMENT
Next Article:BIOWHITTAKER, INC., ANNOUNCES RESULTS OF OPERATIONS
Topics:


Related Articles
BELMAC ENTERS SPANISH MARKET WITH RIMAFAR, S.A.; PHARMACEUTICAL MANUFACTURING CAPABILITY VITAL LINK IN EUROPEAN DISTRIBUTION
BELMAC ANNOUNCES SECOND QUARTER RESULTS
IVAX' SUBSIDIARY RECEIVES APPROVAL TO SELL SODIUM CROMOGLYCATE METERED DOSE INHALER IN THE UNITED KINGDOM
BELMAC REPORTS RESULTS FOR FISCAL YEAR ENDED JUNE 30, 1992
BELMAC REPORTS FIRST QUARTER RESULTS
BELMAC CORPORATION MOVES FORWARD ON EUROPEAN ACQUISITIONS
BELMAC SELLS AMODEX IN FRANCE FOR $3.7 MILLION IN CASH AND LAUNCHES BELMAZOL (OMEPRAZOL) IN SPAIN
BELMAC TERMINATES ACQUISITION DISCUSSIONS WITH TWO EUROPEAN DRUG COMPANIES AND REPORTS RESULTS FOR QUARTER ENDED DEC. 31, 1992
FISONS AND RHONE-POULENC RORER FINALIZE AGREEMENT TO CO-PROMOTE TILADE AND AZMACORT
BELMAC CORPORATION REPORTS SUBSTANTIAL IMPROVEMENT FOR SECOND QUARTER

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters